85 results about "Good prognosis" patented technology

The invention discloses a medicament for treating persistent type cold. The medicament is prepared from 44 active pharmaceutical ingredients such as white stiff silkworm, fructus forsythiae, ephedra herb, cicada shells, lightyellow sophora root, tangerine peel and the like based on a certain mixture ratio by weight. The medicament can be prepared into any one commonly used oral formulation. The medicament can not only treat lung discomfort of a patient with the cold, but also simultaneously treat the symptoms of anorexia and soreness of limbs caused by injuries to the spleen, thereby reducing the occurrence of complications, shortening the rehabilitation period of the patient and achieving good prognosis effect.

This invention relates to a composition, kit, DNA chip, and use thereof for detecting, diagnosing, and predicting metastasis of kidney cancer and / or for predicting the prognosis for kidney cancer, comprising one or a plurality of polynucleotides selected from the group consisting of polynucleotides, mutants thereof or fragments thereof, the expression levels of which vary in kidney cancer cells from a patient with a poor prognosis when compared with that in kidney cancer cells from a patient with a good prognosis; or antibodies or fragments thereof that bind specifically to polypeptides, mutants thereof or fragments thereof, the expression levels of which vary in the similar manner.

The invention discloses gene sets and a scoring model for evaluating a tumor microenvironment, and application of the gene sets, and belongs to the field of biological information. It is proved for the first time that the gastric cancer has remarkable tumor microenvironment typing, and prognosis difference of gastric cancer patients with different typing is remarkable. According to a constructionmethod of the multi-gene scoring model for evaluating the gastric cancer tumor microenvironment, 44 gene sets capable of representing different microenvironment types are screened out, and the prediction efficiency of the tumor microenvironment multi-gene scoring model corresponding to the gene sets is remarkably better than that of other existing models; and the model is not only a prognostic marker of a gastric cancer patient, but also has a quite remarkable prediction effect in pan-cancer. The model provided by the invention not only can be used as a good prognosis biomarker, but also can be used for predicting checkpoint inhibitor immunotherapy response of various tumors by effectively evaluating the tumor microenvironment, and has important significance and clinical application valuefor better screening immunotherapy benefiting people.

A microarray for predicting the prognosis of neuroblastoma, wherein the microarray has 25 to 45 probes related to good prognosis, which are hybridized to a gene transcript whose expression is increased in a good prognosis patient with neuroblastoma and are selected from 96 polynucleotides consisting of the nucleotide sequences of Seq. ID No. 1 to 96 or their partial continuous sequences or their complementary strands, and 25 to 45 probes related to poor prognosis, which are hybridized to a gene transcript whose expression is increased in a poor prognosis patient with neuroblastoma and are selected from 104 polynucleotides consisting of the nucleotide sequences of Seq. ID No. 97 to 200 or their partial continuous sequences or their complementary strands.

The invention relates to a prognosis prediction method, system and equipment, which are applied to prognosis prediction of tumor cell reduction and deactivation and peritoneal hyperthermia perfusion chemotherapy. The invention belongs to the technical field of risk prediction. The method comprises the steps of obtaining prediction parameters of a target individual, and scoring the prediction parameters, thereby obtaining a total score of a prognosis prediction risk value of the target individual; obtaining the one-year survival possibility, the two-year survival possibility or the three-year survival possibility of the target individual through the total score and the preset survival possibility model, so that the prognosis condition of the target individual is judged through the survivalpossibility, and the higher the survival possibility is, the better the prognosis of the target individual is, and the higher the possibility of the long lifetime of the target individual is. A patient or a medical worker can accurately know the prognosis risk of gastric cancer peritoneal cancer treatment through tumor cell reduction and deactivation and abdominal cavity hyperthermia perfusion chemotherapy, and therefore a choice is made.

A method for determining pulmonary fibrosis subtype and / or prognosis in a subject having pulmonary fibrosis comprising: a. determining an expression profile by measuring the gene expression levels of a plurality of genes selected from genes listed in Table 1, 2, 3, 4 7, 8, 9, and / or 10, in a sample from the subject; and b. classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts decreased risk of post lung transplant primary graft dysfunction, and wherein a poor prognosis predicts an increased risk of post lung transplant primary graft dysfunction.

Methods and compositions for detecting a form of chronic lymphocytic leukemia in a subject are described which allow for distinguishing more aggressive forms of the disease from less aggressive forms. Particularly described methods include assaying a sample obtained from the subject having or suspected of having chronic lymphocytic leukemia for a marker selected from a vimentin cleavage product, annexin 5 and 6-phosphogluconolactonase. A combination of any of these markers may be assayed in particular embodiments of a method according to the present invention. In particular embodiments, detection of an intermediate weight vimentin cleavage product is indicative of a less aggressive form of CLL associated with good prognosis.

The invention discloses a kit for colorectal cancer auxiliary diagnosis and / or prognosis. The kit for colorectal cancer auxiliary diagnosis and / or prognosis is developed based on a gene PCDHB3 related to colorectal cancer. The kit comprises at least one of the following reagents of a primer pair for detecting the PCDHB3 gene expression level, a primer pair for detecting the PCDHB3 gene methylation level and the reagent for detecting the PCDHB3 protein level. Differential expression gene screening is conducted on the colorectal cancer, and PCDHB3 located in human body chromosomes 5q31 is the gene closely related to the colorectal cancer. The mRNA and protein expression level of the PCDHB3 is remarkably decreased in the tumor tissue of a colorectal cancer patient, and the decrease is closely related to gene promoter region CpG basic group height methylation. Meanwhile, prognostic analysis of the TNM III-IV stage colorectal cancer patient shows that the PCDHB3 indicates good prognosis in tumor cell high-level expression or tumor cell karyotheca expression.

The present invention provides that ERRγ is both a breast cancer biomarker and a breast cancer treatment target. A high ERRγ level in breast cancer cells indicates good prognosis. A high level of ERRγ in breast tissue suspected of being cancerous is indicative of breast cancer. Analyzing ERRγ status and optionally along with the status of ERα can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by decreasing ERRγ activity in breast cancer cells.

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt / β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt / β-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.

The invention discloses a hysteromyoma excision system under a hysteroscope combined with a laparoscope. The system comprises a laparoscope system, a hysteroscope system and an imaging system. The laparoscope system is separately connected with a light source illumination module, an optical imaging module and an ultrasonic imaging module in the imaging system; the hysteroscope system is separatelyconnected with the light source illumination module and the optical imaging module in the imaging system and comprises an excision instrument for integrally excising the hysteromyoma. According to the hysteromyoma excision system under the laparoscope combined with the laparoscope, an ultrasonic probe is additionally arranged in the laparoscope, an ultrasonic image is fused with a preoperative magnetic resonance image, and therefore invisible myometrial myomas can be precisely imaged; the myomas under the hysteroscope are integrally excised so as to avoid the residues of myoma tissue fragments, and therefore the comprehensive excision of the hysteromyoma is realized; the hysteromyoma excision system has the advantages of convenient operation, small wounds, less bleeding, quick recovery, high myoma stripping rate and the like, can effectively reduce the residual rate and the relapse rate after an operation and has a good prognosis effect.

The invention relates to the technical field of medical molecular biology, in particular to a prognosis evaluation method for immunotherapy of a non-small cell lung cancer patient, which comprises the following steps: detecting gene variation through sequencing, creating a decision tree model, screening 13 optimal characteristic genes, and constructing a prediction model to carry out prognosis risk scoring on the non-small cell lung cancer TMB-H patient. Therefore, the prognosis condition of the patient is predicted. Compared with the prior art, the prognosis evaluation method for the immunotherapy of the non-small cell lung cancer TMB-H patient, provided by the invention, has the advantages that the non-small cell lung cancer TMB-H patient sample is sequenced, the prediction model containing 13 optimal characteristic genes is constructed based on a CART algorithm, prognosis risk scoring is carried out on non-small cell lung cancer TMB-H patients according to the prediction model, TMB-H people are divided into a good prognosis group and a poor prognosis group, and the accuracy rate is up to 0.85.

The present invention relates to an in vitro method for the prognosis of the survival time of a patient suffering from a solid cancer, comprising the quantification of the cell density of follicular B cells present in tumor-induced lymphoid structures from said patient, wherein a high density of follicular B cells indicates that the patient has a favorable prognosis and a low density of follicular B cells indicates that the patient has a poor prognosis.

The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8 / A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8 / A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8 / A9 complex below the predetermined threshold is indicative of a good prognosis.

The present invention relates to a method and system for selecting a customized drug using information of cancer genomic nucleotide sequence variations and patient survival and, more specifically, toa method and system for selecting a customized anticancer therapeutic drug using variation information of a synthetic cancer survival gene among cancer genomic nucleotide sequence variations. The method and system for customized anticancer therapy of the present invention using information of cancer genomic mutations and patient survival or the evaluation of invasive or metastatic ability of cancer cells or tissues correspond to a technique to effectively select an anticancer therapeutic drug having a good therapeutic effect and prognosis according to the individual through the variation analysis of synthetic cancer survival gene pairs, which is derived from the information of cancer genomic nucleotide sequence variations and cancer survival and metastasis, and the method and system of thepresent invention have high reliability and can provide related information promptly and simply.

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tissue sample obtained from the patient the gene expression level of FcRn ii) comparing expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when expression level determined at step i) is higher than their predetermined reference value, or providing a bad prognosis when expression levels determined at step i) are lower than their predetermined reference values.

The invention discloses application of SFRP4 as a gastric cancer prognosis marker, belongs to the field of tumor molecular biology, and further discloses application of the SFRP4 as a treatment target in preparation of gastric cancer treatment drugs, expression up-regulation of the SFRP4 in gastric cancer tissues is remarkably related to poor prognosis; the SFRP4 is obviously related to abundance of various lymphocytes, immunomodulators and chemotactic factors in gastric cancer tissues, so that the survival time of a patient can be better predicted, even the state of an immune microenvironment can be evaluated, and the SFRP4 is a potential useful and reliable biomarker for guiding immunotherapy and determining prognosis of the gastric cancer patient. The invention also provides an application of the SFRP4 combined with CD8 + T as a gastric cancer prognosis marker, the gastric cancer prognosis can be better predicted by combining the SFRP4 combined with the CD8 + T, and the good prognosis of a patient is prompted by the low expression of the SFRP4 and the high infiltration of CD8 + T cells in a tissue sample.

The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.

The prognosis of a cancer patient can be determined by analyzing the modulation of expression of specified genes in the tumor tissue. Genes uniquely up-regulated in adult stem cells that can reconstitute the tissue of the tumor are analyzed for up-regulation in the patient's tumor. Up-regulation of a plurality of such genes in the tumor is an indication of good prognosis. Genes uniquely up-regulated in fetal stem cells are analyzed for up-regulation in the patient's tumor. Up-regulation of a plurality of such genes in the tumor are an indication of a poor prognosis. Specific genes are disclosed, the modulation of which, in a patient's prostate cancer tumor, will serve as an indication of prognosis. Patients with a good prognosis are subjected to watchful waiting. Patients with a poor prognosis are aggressively treated. Kits are provided containing a set of affinity reagents that specifically detect expression of the various genes.

The invention discloses an ovarian cancer drug-resistance marker UTP23, an expression ratio of an existing gene GDF15 and related prognosis of ovarian cancers. Particularly, when the ratio is low, anovarian cancer case shows poor prognosis according to prognostic indicators such as chemotherapy sensitivity, drug resistance, satisfactory cytoreductive surgery, progression free survival and overallsurvival. When the ratio is high, an ovarian cancer patient shows good prognosis, namely, clinical therapy of the ovarian cancers includes chemotherapy and surgical therapy to provide prognosis prompt.

The invention provides a group of molecular probes for detecting and evaluating a gene set of a tumor microenvironment. The molecular probes comprise 44 nucleotide sequences as shown in SEQ ID NO: 1-44. A screened probe is used for carrying out NanoString digital expression detection on the expression of a target gene in a same hole, a digital gene expression profile is drawn, and the probe can be used for evaluating the immunotherapy effect. The invention further provides a construction method of a multi-gene scoring model for evaluating the gastric cancer tumor microenvironment, and 44 gene sets capable of representing different microenvironment types are screened out and can be used for establishing the tumor microenvironment multi-gene scoring model for evaluating patients. By effectively evaluating the tumor microenvironment, the model not only can be used as a good prognosis biomarker, but also can predict checkpoint inhibitor immunotherapy response of various tumors, and has important significance and clinical application value for realizing individualized medical treatment and saving medical resources at the same time.

The present invention provides methods and kits to obtain an early evaluation of mortality risk and help therapeutic decisions for patients in severe sepsis with two organ failures, for example for patients in septic shock. The invention is based on the measure of the level of S100A8 / A9 complex in plasma, since a level of S100A8 / A9 above a predetermined threshold is indicative of a bad prognosis and a level of S100A8 / A9 below said predetermined threshold is indicative of a good prognosis.

The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.The method of the present invention has an effect of being capable of more accurately predicting the future prognosis of metastasis, recurrence, or metastatic recurrence in breast cancer patients, and in particular, has a very excellent ability to predict the prognosis of HER2-type breast cancer, the prognosis of which is very poor, and thus can be usefully used to provide clues for the direction of future treatment of breast cancer.

The invention discloses an extranodal nasal NK / T cell lymphoma prognostic marker, an application thereof, a prognostic prediction model and a construction method thereof. The prognostic marker is remarkably related to disease staging and Ki67 positive rate, and the prognostic marker is CD20; it is found for the first time that the infiltration density of CD20 positive cells in the extranodal nasalNK / T cell lymphoma tumor tissue is positively correlated with the survival time of a patient, and is negatively correlated with the disease staging of the patient; it shows that CD20 can be used as aprediction index for good prognosis of the patient; the prognostic marker CD20 can make up for the deficiency of good prognostic prediction indexes in the ENKTCL field; the construction method of theprognosis prediction model is simple; the density of CD20 positive cells in a tumor tissue slice of the patient is detected by combining an immunohistochemical method with a slice microscanning technology and the like, so that a patient prognosis prediction model is constructed; and the patient prognosis prediction model has great significance in guiding individualized treatment of clinical extranodal nasal NK / T cell lymphoma.

The invention discloses a super-mutant type tumor molecule subtype gene capable of distinguishing patients with poor prognosis and good prognosis of super-mutant type colorectal cancer, squamous-cellcarcinoma and skin melanoma. Doctors can be reminded to take different treatment methods for two groups of patients, good benefits can be made through immunotherapy for patients with poor prognosis, and good clinical instruction significances can be made. The invention further discloses a kit for capturing the gene.

A microarray for assessing prognosis of neuroblastoma having 25 to 45 good prognosis probes selected from among 96 polynucleotides which are hybridizable with a gene transcriptional product showing accelerated expression in patients showing good prognosis of neuroblastoma and comprise the base sequence represented by SEQ ID NOS:1 to 96, partial consecutive sequences thereof or complementary chains of the same, and 25 to 45 poor prognosis probes selected from among 104 polynucleotides which are hybridizable with a gene transcriptional product showing accelerated expression in patients showing poor prognosis of neuroblastoma and comprise the base sequence represented by SEQ ID NOS:97 to 200, partial consecutive sequences thereof or complementary chains of the same.

The invention discloses a scalp separating cutter which structurally comprises a handle, a connecting device, a cutter main body, a blade fixing pile, a cutter head clamping groove and a separating end. The connecting device is arranged between the cutter main body and the handle, a fixing piece is disassembled through a fixing hole, and then the fixing hole is separated from the connecting main body through an inner shaft rod, and then an inner shaft rod is separated in the connecting main body, so that the problem is solved that the space is occupied when the scalp separating cutter is placed after the scalp separating cutter is used. The back portion is of a handheld wood handle structure, so that comfort and stability during surgical cutting are improved, a blade is reversely fixed, scalp and subcutaneous tissues can be effectively separated when the scalp is cut in front of the scalp cutter, tissues such as the fascia, muscles, blood vessels, periosteum and the like are preventedfrom being cut by mistake, intraoperative bleeding is reduced, operation time is saved, and guarantee is provided for good prognosis of patients.

Provided herein are methods for selecting a drug therapy for a patient with cancer, such as colorectal cancer, pancreatic cancer, lung cancer or breast cancer. The method includes determining or measuring the level of RasGRP1 polynucleotide or polypeptide in a sample from the patient. Also provided herein are methods for determining the likelihood of a good prognosis for a patient with cancer. Additionally, provided herein are methods for predicting the likelihood of a negative clinical response to an anti-EGFR therapy in a subject with cancer.